Musk said in a 2019 public presentation that Neuralink, which he launched in 2016, aims to receive regulatory approval by the end of 2020. An FDA spokesman did not immediately respond to a request for comment. It's unclear where Neuralink stands in its application with the US Food and Drug Administration (FDA) to initiate human trials. That frustration was not conveyed to Oxley when Musk reached out to him. The approach comes after Musk, who is also chief executive of electric car maker Tesla Inc and owner of rocket developer SpaceX, expressed frustration with Neuralink employees over their slow progress. A Synchron spokesman also declined to comment. Representatives for Musk and Neuralink did not respond to requests for comment. This source specifically requested anonymity as this matter is confidential. It has not yet been decided whether they will accept the investment and there is no definite agreement, the source added. "Synchron, based in the Brooklyn, New York City area, is ahead of Neuralink in the process of winning regulatory clearance for its devices," the source said. It is unclear whether any of the transactions involved ties or collaborations between Synchron and Neuralink. Musk contacted Synchron founder and chief executive Thomas Oxley in recent weeks to discuss a possible deal, a source familiar with the matter told Reuters. JAKARTA - Elon Musk has approached brain chip implant developer Synchron Inc for potential investment as his own company, Neuralink, is catching up in the race to connect the human brain directly to machines.
0 Comments
Leave a Reply. |